

# JANUS KINASE 2 (JAK2) V617F ALLELIC BURDEN TEST

## **CLINICAL INFORMATION**

Somatic Mutation of the JAK2 gene (JAK2 p.V617F) can be detected in a variable proportion of patients with myeloproliferative neoplasms. The JAK2 p.V617F mutation is observed in as much as 96% of the patients with Polycythemia Vera and approximately 55% to 65% of those with essential thrombocythemia and primary myelofibrosis. In addition, quantitative measurement of the JAK2 p.V617F allele burden (ratio of mutant allele to total allele) has been associated with certain clinical phenotypes, such as higher incidence of pruritus and splenomegaly and an increased risk of thrombosis in patients with PV & ET.

#### **KEY FEATURES**

## JAK2 ALLELIC BURDERN RTPCR KIT

- Easy-to-use reagents
- Complete Allelic discrimination and quantitative kit
- Validated on >2000 NABL samples.
- Validated with all major extraction and amplification platforms
- Designed for low to high throughput analysis
- Ultra-High Specificity & Sensitivity. Detection Limit of 0.002

### **TECHNICAL INFORMATION**

PRODUCT CODE	STRUMBJAK50
TEST/PARAMETERS	Janus kinase 2 (JAK2) V617F allelic Burden test
Principle of the test	Taqman 5'Nuclease Allelic Discrimination Assay
Туре	Allelic Discrimination and Quantitation
Technology	Real Time PCR
Gene target	V617F
Range Detection	NA
Specimen	Blood
MGB Probe	Yes (n=2); 1=Wild allele; 2: Mutant allele.
Detection limit	0.002
Controls included	(1) Quantitation standards (n=4) - Wild allele
	(2) Quantitation standards (n=4)-mutant allele
Reporting unit	Copies/uL
Number of tests	50
Storage conditions	-20 Degree C
Validation platform	Rotorgene (Qiagen)
	Applied Biosystems
	Roche
Status	Research Use Only
NABL Samples Validated	Yes

#### STRUMED SOLUTIONS PRIVATE LIMITED